Phase III clinical trials for a stem cell based ALS treatment has been initiated. ALS, or amyotrophic lateral sclerosis, is a disorder in which motor neurons in the body rapidly degenerate, and the treatment aims to prolong the survival rate of afflicted individuals by using autologous [the patient’s own] mesenchymal stem cells (the same stem cells found in teeth), which can be differentiated into fully-functioning neurons. The trials, to be conducted by BrainStorm Therapeutics, exploits the company’s proprietary technology [NurOwn], which utilizes mesenchymal stem cells. BrainStorm obtains these cells from the patient, expanding and differentiating the stem cells prior to application. The stem cells begin producing neurotrophic factors that facilitate neuronal growth and regeneration.
Building on NurOwn’s success in the previous clinical trials, 200 patients are expected to participate in this stage of the clinical trial. The trials will be conducted in several locations across the U.S. including California Pacific Medical Center, the Mayo Clinic, University of California Irvine, and the University of Massachusetts Medical School, with the trials having already begun at the Massachusetts General Hospital in early September 2017. If proven successful, an effective treatment for the devastating degenerative effects of ALS could soon be accessible to ALS sufferers.
BrainStorm’s innovative research demonstrates the integral role stem cells are playing in cutting edge medical care options. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.